Immunome Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2023 at the 2023-06-07 meeting.
“Proposal 3: Ratification of the Selection of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2023 The selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2023 was ratified, with the following votes tabulated: For Against Abstain Total 7,578,396 153,921 3,141 7,735,458”
Shareholder Votes
Immunome Inc. shareholders rejected Amendment to Our Amended and Restated Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer Exculpation at the 2023-06-07 meeting.
“Proposal 2: Amendment to Our Amended and Restated Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer Exculpation The amendment of the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation was not approved by an affirmative vote of a majority of the shares of common stock outstanding and entitled to vote at the Annual Meeting, with the following votes tabulated: For Against Abstain Broker Non-Vote Total 3,528,592 86,542 4,771 4,115,553 7,735,458”
Shareholder Votes
Immunome Inc. shareholders approved Election of Class III Directors for a Three-Year Term Expiring in 2026 at the 2023-06-07 meeting.
“Proposal 1: Election of Class III Directors for a Three-Year Term Expiring in 2026 The following three nominees were elected to serve as Class III directors until the 2026 Annual Meeting of Stockholders of the Company and until their respective successors are elected and qualified, with the following votes tabulated: For Withheld Broker Non-Vote Total Richard A. Baron 2,897,767 722,138 4,115,553 7,735,458 Philip Wagenheim 3,287,880 332,025 4,115,553 7,735,458”
Earnings Releases
Immunome Inc. reported the first quarter ended March 31, 2023 results: revenue $2.4 million, net income $4.3 million.
“including ADCs. Financial Highlights · Collaboration Revenue : Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended March 31, 2023 was $2.4 million. · Research and development (R&D) expenses: R&D expenses for the three months ended March 31, 2023 were $3.9 million. · General and administrative (G&A) expenses: G&A expenses,”
Material Agreements
Immunome Inc. entered into Collaboration Agreement with AbbVie Global Enterprises Ltd. valued at $30 million (effective 2023-01-04).
“On January 4, 2023, Immunome, Inc. (the “ Company ”) entered into a collaboration and option agreement (“ Collaboration Agreement ”) with AbbVie Global Enterprises Ltd. (“ AbbVie ”),”
Material Agreements
Immunome Inc. amended Letter Agreement with Whitehead Institute for Biomedical Research (effective 2023-01-04).
“On November 17, 2022, Immunome, Inc. (the “Company”) entered into a Letter Agreement (“Letter Agreement”) with the Whitehead Institute for Biomedical Research (“Whitehead”), which became effective on January 4, 2023 upon the satisfaction of the conditions described therein. The Letter Agreement supplements the Exclusive Patent License Agreement entered into between the Company and Whitehead on June 25, 2009 (as amended on December 17, 2009, March 21, 2013, August 21, 2017 and July 21, 2020, the “License Agreement”).”
Earnings Releases
Immunome Inc. reported third quarter ended September 30, 2022 results: net income $8.5 million.
“Net loss: Net loss for the three months ended 2022 was $8.5 million.”
Michael J. Morin was appointed as Chief Scientist at Immunome Inc..
“Dr. Morin resigned from his positions as Chief Scientific Officer and Executive Vice President of the Company. Pursuant to the Employment Agreement, Dr. Morin will be employed by the Company on a part-time basis as its Chief Scientist.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.